Research
Retatrutide improved sleep apnea in two trials of adults with obesity
At 80 weeks, retatrutide reduced apnea-hypopnea index more than placebo in adults with obesity, including those with type 2 diabetes.
Retatrutide improved obstructive sleep apnea (OSA) in two phase III randomized trials of adults with obesity or overweight, according to findings reported in the New England Journal of Medicine. One trial enrolled people without type 2 diabetes, and the other enrolled people with type 2 diabetes.
At 80 weeks, apnea-hypopnea index fell by 24.4 and 21.9 events per hour more than placebo with 9 mg and 12 mg doses, respectively, in the trial without type 2 diabetes. In the trial with type 2 diabetes, reductions were 14.4 and 15.1 events per hour more than placebo, respectively. The researchers said all differences in the primary endpoint met statistical significance.
The trials included 243 and 448 participants. Both enrolled adults with moderate-to-severe OSA and a body mass index of at least 27, who received once-weekly retatrutide or placebo. The most common adverse events were gastrointestinal. The reports did not specify a next step for the trials.
